Counts describe this library, not the strength of evidence.
Cómo interpretar la evidencia
Strength, muscle size and function are related but distinct outcomes. Trials and reviews support progressive resistance exercise, while longevity cohorts cannot establish exact safe-dose limits. More complicated prescriptions do not consistently outperform achievable basics.
In this pilot trial of prostate cancer patients on androgen deprivation therapy (ADT), 12 weeks of supervised resistance training improved lean mass (d = 0.9), body fat % (d = 1.1) and strength compared with stretching (p < 0.05), while metabolic syndrome measures and physical function did not change. Only 32 of 37 randomized people took part, so the results are preliminary.
Sarcopenia was diagnosed in 13 of 83 outpatients with type 2 diabetes (16.2%) versus 2 of 83 matched controls (2.4%; p = 0.01168). This is a single-clinic, cross-sectional comparison, so it shows an association and cannot show that diabetes causes sarcopenia.
Pooling 10 studies for strength and 10 for power, caffeine improved maximal strength (SMD 0.20, 95% CI 0.03 to 0.36) and jump power (SMD 0.17, 95% CI 0.00 to 0.34) over placebo. The effects are small and borderline, and the lower-body strength result was not significant (SMD 0.15, P = 0.147).
Journal of the International Society of Sports Nutrition
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
Among 722 community-dwelling people aged 85 and over, the 390 (54%) who ate under 1 g protein/kg adjusted body weight/day had 1.62 kg lower grip strength (p = 0.008), but protein intake was not linked to how fast grip declined over 5 years. The study is observational and diet was measured at baseline, so lower protein may be a marker of poorer health rather than the cause of weakness.
In 106 adults aged 65 to 75, resistance training raised environmental quality of life and, at twice a week, sense of coherence compared with the groups that trained once or three times weekly or did not train (group × time p = .011 and p = .032). The groups were small, with 25 to 28 people each, and the findings come from several secondary comparisons, so they are suggestive.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
A systematic review of 72 studies that used handgrip strength to diagnose sarcopenia (37 studies) or frailty (33 studies; 2 covered both) found that most gave limited information about the test protocol. The authors conclude that high protocol heterogeneity makes comparison across studies very difficult. It is a review of methods, not of how well grip tests work.
Among 834 community-dwelling Chinese adults aged 60 and over, 10.6% had sarcopenia, and more frequent nut eating (adjusted OR 0.724) and higher family function scores (adjusted OR 0.683) were each linked to lower odds of it. Because everything was assessed in the same group at one point, the direction of these links is unknown.
In a 6-month trial of 160 obese, mildly to moderately frail adults aged 65 or older, a weight-loss programme plus combined aerobic and resistance exercise raised the Physical Performance Test score by 5.5 points, against 3.9 points for either exercise type alone and 1.0 for controls. Every exercise group still lost lean mass, and all but the resistance group lost hip bone density, so the combined programme softened these losses rather than preventing them. The volunteers were screened, trained under supervision and were mostly white, well-educated women.
Pooling 35 articles and 58404 adults aged 60 or older, the estimated sarcopenia prevalence was 10% in men (95% CI 8-12%) and 10% in women (95% CI 8-13%). Prevalence was higher in non-Asian than Asian people when muscle was measured by bioelectrical impedance, and the abstract notes the studies used different tools and regions.
In a meta-analysis of prospective studies, people with sarcopenia had higher odds of death (pooled OR 3.596, 95% CI 2.96-4.37) and of functional decline (pooled OR 3.03, 95% CI 1.80-5.12). Most outcomes besides mortality rest on very few studies, so those results are less certain.